Form 4: Aquestive Therapeutics Insider Tax Withholding Filing

Corporate Secretary Lori J. Braender disposed of 76,147 shares of Aquestive Therapeutics to satisfy tax obligations related to PSU vesting.

Summary

• Lori J. Braender, Corporate Secretary of Aquestive Therapeutics, Inc., reported the disposition of 76,147 shares of common stock.
• The transaction occurred on May 5, 2026, at a price of $4.18 per share.
• The shares were withheld by the company to cover tax withholding obligations resulting from the vesting of Performance Stock Units (PSUs).
• Following this transaction, the reporting person maintains a beneficial ownership of 366,732 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the share reduction is purely administrative and related to tax compliance rather than a change in management sentiment.

Positives

• The transaction was a routine administrative action to satisfy tax obligations rather than a discretionary market sale.

Negatives

• The transaction represents a reduction in the direct equity stake held by a key member of the corporate leadership team.

Risks

• None identified; this is a standard regulatory disclosure regarding tax withholding.

Future Outlook

No forward-looking guidance or strategic outlook was provided in this regulatory filing.

Industry Context

StockSavvy.ai notes that this filing is a standard administrative disclosure common in the biotechnology sector, where equity-based compensation is a primary tool for executive retention and alignment.

Comparison to Industry Standards

• The use of 'sell-to-cover' or share withholding for tax obligations is a standard practice among publicly traded companies to manage the tax liabilities of employees upon the vesting of equity awards.

Stakeholder Impact

• Minimal impact on shareholders as the transaction was a non-discretionary tax withholding event.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

Aquestive Therapeutics, AQST, Form 4, Insider Transaction, Tax Withholding, Equity Vesting